Bank of America Corp DE lifted its stake in Mesoblast Limited (NASDAQ:MESO - Free Report) by 1,503.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 290,728 shares of the company's stock after purchasing an additional 272,595 shares during the period. Bank of America Corp DE owned 0.23% of Mesoblast worth $5,756,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of MESO. Lindbrook Capital LLC boosted its position in shares of Mesoblast by 70.9% in the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock worth $43,000 after purchasing an additional 901 shares during the period. R Squared Ltd bought a new position in Mesoblast in the 4th quarter worth $30,000. Prosperity Wealth Management Inc. increased its stake in Mesoblast by 2.0% in the 4th quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company's stock worth $1,846,000 after buying an additional 1,795 shares in the last quarter. Quadrant Capital Group LLC increased its stake in Mesoblast by 41.1% in the 4th quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company's stock worth $129,000 after buying an additional 1,891 shares in the last quarter. Finally, Barclays PLC bought a new stake in Mesoblast during the fourth quarter valued at about $38,000. 1.43% of the stock is owned by institutional investors.
Mesoblast Stock Performance
Shares of MESO traded down $0.07 during midday trading on Friday, hitting $10.61. 176,506 shares of the company traded hands, compared to its average volume of 270,454. The firm has a 50 day moving average of $11.33 and a 200-day moving average of $13.95. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. Mesoblast Limited has a 52 week low of $5.78 and a 52 week high of $22.00.
Analyst Upgrades and Downgrades
MESO has been the subject of a number of recent analyst reports. Piper Sandler reaffirmed an "overweight" rating and issued a $24.00 price objective (up previously from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a research note on Monday, March 31st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.
Read Our Latest Stock Analysis on Mesoblast
About Mesoblast
(
Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Read More
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
